Home Boston Scientific

Boston Scientific

PINNACLE FLX Study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device Presented as Late-Breaking Clinical Trial at HRS 2020 SCIENCE

Presented as a late-breaking clinical trial at HRS 2020 SCIENCE, the study evaluated performance of the WATCHMAN FLX™ device as an alternative to oral anticoagulation therapy, including non-vitamin K antagonist oral anticoagulants (NOACs), for stroke risk reduction in patients with NVAF.

New Clinical Study Results Demonstrate Rezūm is Proven to Give Men Suffering with BPH Sustained Symptom Relief and Quality of Life Improvements for 5...

The supplement, available online now, includes standard and late-breaking abstracts for the American Urological Association (AUA) Annual Meeting.

World’s First Single-Use Duodenoscope, EXALT™ Model D Receives FDA Clearance

The EXALT Model D Duodenoscope is the first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.

Tactra™ Malleable Penile Prosthesis Launched by Boston Scientific

The new penile prosthesis is the first new innovation in penile implants in more than 10 years and represents an evolution in the design of malleable penile implants to offer the patient and his partner a more authentic, natural-feeling erection.

April 24, 2019: LOTUS Edge ™ Aortic Valve System FDA Approval

The LOTUS Edge valve system is the only FDA-approved aortic valve that gives physicians the option to reposition and completely recapture the valve once it has been fully deployed. It also features a braided valve frame and an adaptive seal that minimizes paravalvular regurgitation or leaking (PVL) by conforming to the patient's native aortic valve.

Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device Receives CE Mark

3/13/19: The WATCHMAN device has been implanted in more than 75,000 patients worldwide and we are pleased that this next-generation technology has been granted European regulatory approval so that we can offer it to patients and clinicians throughout Europe.

Boston Scientific Launches Spectra WaveWriter™ Spinal Cord Stimulator System in Europe

1/31/19: Spectra WaveWriter™ Spinal Cord Stimulator allows physicians & patients to specifically target one area of pain, or multiple areas, with one or both types of therapy to address individual needs.

Boston Scientific Exercises Option to Acquire Millipede, Inc.

12/27/18: Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system.